Yoshiaki Sato, MD, PhD (he/him/his)

Director, Associate Clinical Professor
Nagoya University Hospital
Nagoya, Aichi, Japan

Presentation(s):

• Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial): outcome at 3 years old.

  Saturday, April 26, 2025
  2:15pm – 2:30pm HST

  Disclosure(s): Life Science Institute, Inc. (Terminated, March 31, 2023) (Products/Services: Contractor including contracted research); S-Quatre Corporation (Ongoing) (Products/Services: Contractor including contracted research)